ONGOING PHASE 2, OPEN‐LABEL, MULTICENTER, SINGLE‐ARM STUDY ASSESSING AN EVERY‐4‐WEEK DOSING SCHEDULE OF MOGAMULIZUMAB IN CUTANEOUS T‐CELL LYMPHOMA: PRELIMINARY RESULTS | Publicación